JG
SRNE

Jefferies Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Jefferies Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-50,000
Closed -$341K – 2096
2020
Q4 		$341K Sell
50,000
-50,000
-50% -$402K ﹤0.01% 1249
2020
Q3 		$1.11M Buy
+100,000
New +$915K 0.01% 762

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Jefferies Group's SRNE Position: Q4 2020 in Review

Jefferies Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 4,524 shares — an estimated $36.3K sold.

Jefferies Group first reported a position in SRNE in Q1 2018 and held it in 4 quarters. The position peaked at $159K in Q3 2018. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Jefferies Group reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Jefferies Group sold 4,524 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $36.3K.
  • Jefferies Group first reported a position in Sorrento Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
  • Jefferies Group's Sorrento Therapeutics, Inc. position peaked at $159K in Q3 2018.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Jefferies Group's 13F filing for Q4 2020, filed 16 Feb 2021.